Abstract:Objective To evaluate the efficacy of a tolterodine tartrate based combined drug therapy in the treatment of severe female urethral syndrome(FUS).Methods Twenty-three female US patients diagnosed with severe female urethral syndrome were recruited in this prospective 2-month clinical trial. The average course of patient's history was (40.7±11.6) months, ranging from 19 to 72 months. All 23 patients were observed with severe urination frequency(>30/day, >10/night), urination urgency, urination pain and frequent acute pelvic pain, along with psychological symptoms such as loss of faith in treatment, neuroticism, suicidal mentality, anxiety, etc. Among 23 patients, 3 patients had lost self-care ability, 1 patient had lost exercise ability, 2 patients had suicidal tendency, 1 patient had suicidal behavior. According to individual patient conditions and symptoms, combined drug therapies, including α-receptor blocker, estrogen, low addictive pain killer, anti-histamine drug, antidepressant drug and sedative drug were applied. Basic dosage of tolterodine tartrate is 2 mg bid, and dosages of other drugs were conventional. The treatment normally starts with α-receptor blocker and low addictive pain killer. Antidepressant drug and estrogen were applied to patients with strong psychological symptoms and abnormal estrogen level when the therapy started. All 15 patients were re-examined one week after the therapy. For patients observed with obvious improvements, the therapy remained the same. For patients with non-obvious improvements, more combined drugs would be applied based on the patient's conditions. For patients with severe symptoms or not responsive to the initial therapy, multi-drugs were combined in the beginning of the therapy. The trail went on for 2 months. Pre-treatment and post-treatment patient clinical symptoms(daily urination frequency, urination pain score and pelvic pain occurrences) were observed. Side effects were recorded.Results (1)Daily urination frequency was obviously lower after the 2-month trial. Frequencies were improved from (31.5±4.4) times per day for pre-treatment to (16.6±3.2) times per day for post-treatment. Pelvic pain occurrences were much less after the 2-month trial. Occurrences were reduced from (15.6±2.7) times per week for pre-treatment to (2.4±1.6) times per week for post-treatment. Both above results were statistically significant(P<0.01). (2)Urination pain scores lowered substantially from (6.8±1.1) for pre-treatment to (3.7±1.5) for post-treatment. Pelvic pain were eased much and quality of life scores(QOL) were substantially lowered from (5.8±0.6) for pre-treatment to (2.2±0.8) for post-treatment. The pre-treatment and post-treatment differences were statistically significant (P<0.01). (3)Psychological symptoms were substantially improved and suicidal tendencies were removed. (4)There was no obvious main complaint from all 15 patients. Considering the side effects influences might be masked by improved psychological conditions resulted from relieved symptoms, side effects of the therapy relies on further clinical studies.Conclusion A tolterodine tartrate based, patient-specific, combined drug therapy can quickly and effectively relieves the clinical symptoms of severe female urethral syndrome(SFUS), and improves quality of life and psychological conditions of the patients. The side effects are well tolerated.

Clinical study on combined drug therapy of severe female urethral syndrome

Clinical Observation on Heat Sensitive Moxibustion Combined with Abdominal Acupuncture Therapy and Kegel Exercise in Treating 28 Females' Stress Urinary Incontinence

Efficacy and Safety of Combined Therapy with Terazosin and Tolteradine for Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia: a Prospective Study

Disease Correlation and Effects of Pelvic Floor Muscle Training on Tolterodine Based Treatment for Female Primary Overactive Bladder Syndrome

[A Combination of Solifenacin Succinate and Naftopidil in the Treatment of Female Overactive Bladder].

The Efficacy of Different Methods in Treatment of Female Urethral Syndrome

Effect of tolterodine combined with Suoquan pill on overactive bladder in postmenopausal women

Medical Expulsive Therapy for Ureteral Calculi with Tamsulosin: Evidence from A Meta-analysis of Randomized Controlled Trials

Comparison of Effect Between the Treatment of Tolterodine Combined with Naftopidil and of Tolterodine Alone on Female Overactive Bladder

Combination of Tamsulosin and Tolterodine Alleviates Refractory Lower Urinary Tract Symptoms in Male Patients

The concomitant use of fesoterodine and topical vaginal estrogen in the management of overactive bladder and sexual dysfunction in postmenopausal women

Tamsulosin Combined with Solifenacin Versus Tamsulosin Monotherapy for Male Lower Urinary Tract Symptoms: a Meta-Analysis

Application effects of solifenacin combined with tamsulosin in the mild and moderate benign prostatic hyperplasia with overactive bladder

Effectiveness of combined therapy with terazosin and tolterodine for patients with benign prostatic hyperplasia

Efficacy and safety of pelvic floor magnetic stimulation combined with mirabegron in female patients with refractory overactive bladder: a prospective study

Transcutaneous electrical nerve stimulation and solifenacin succinate versus solifenacin succinate alone for treatment of overactive bladder syndrome: A double-blind randomized controlled study

Efficacy and Safety of Solifenacin Plus Tamsulosin Oral Controlled Absorption System in Men with Lower Urinary Tract Symptoms: a Meta-Analysis

Effects of Tolterodine Combined Tamsulosin on Ureteral Stent Related Symptoms

Combination of Solifenacin and Tamsulosin May Provide Additional Beneficial Effects for Ureteral Stent-Related Symptoms—outcomes from a Network Meta-Analysis

Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome

Efficacy Of Combined Amlodipine/Terazosin Therapy In Male Hypertensive Patients With Lower Urinary Tract Symptoms: A Randomized, Double-Blind Clinical Trial